Katrina S. Pedersen, MD, MS

Articles

The Role of Chemotherapy in Third-Line mCRC Treatment

July 16th 2025

Panelists discuss how they approach rechallenge with chemotherapy, considering it primarily in patients who never truly progressed on oxaliplatin-based therapy or those who might benefit from EGFR antibody reintroduction after a drug holiday.

Fruquintinib in Practice: Nuances of Treatment Management and Future Combination Approaches

July 16th 2025

Panelists discuss how they manage fruquintinib dosing by starting at lower doses (3-4 mg) in patients with poor performance status or frailty, then titrating up as tolerated rather than starting at the full 5 mg dose.

SUNLIGHT Regimen in Third-Line mCRC: Insights on Treatment Management and Practical Nuances

July 9th 2025

Panelists discuss how they modify dosing schedules for TAS-102 (trifluridine/tipiracil), with some preferring every-other-week dosing instead of the standard 2-weeks-on schedule to reduce neutropenia and improve tolerability.

Role of Regorafenib in Third-Line mCRC: Expert Insights on Treatment Strategies and Management Nuances

July 9th 2025

Panelists discuss how clinical trials remain the preferred option in third-line treatment, while acknowledging that regorafenib may benefit from dose reduction strategies and potential combination with immunotherapy in select patients.

A Review of the Treatment Options in Third-Line mCRC and Therapy Sequencing Strategies

June 30th 2025

Panelists discuss how 3 drugs (regorafenib, TAS-102, and fruquintinib) offer modest but meaningful survival benefits in treatment-refractory colorectal cancer, with TAS-102 plus bevacizumab being the preferred combination when tolerated.

The Role of ctDNA in the Management of mCRC

June 30th 2025

Panelists discuss how circulating tumor DNA testing serves as the best prognostic technology available, particularly useful for identifying high-risk stage II patients who would benefit from adjuvant therapy, though surveillance strategies for positive results remain unclear.

CheckMate 8HW Expanded Analysis at ASCO 2025: Implications for Treatment Decisions in MSI-H mCRC

June 23rd 2025

Panelists discuss how doublet immunotherapy with ipilimumab and nivolumab provides superior outcomes compared to single-agent PD-1 therapy or chemotherapy in microsatellite instability-high colorectal cancer, supporting the “hit hard, hit early” approach.

Expert Insights: BREAKWATER Survival Data Update From ASCO 2025

June 23rd 2025

Panelists discuss how the BREAKWATER trial demonstrates that upfront treatment with encorafenib plus cetuximab significantly improves outcomes in BRAF V600E-mutated colorectal cancer, turning a historically poor prognostic marker into a targetable opportunity.

DPD Testing and Medication Dosage Adjustments in mCRC Patients

June 16th 2025

Panelists discuss how dihydropyrimidine dehydrogenase testing remains controversial with institutions debating whether to implement universal pharmacogenomic testing given the challenges of standardization, genotype-phenotype correlation, and low incidence of severe deficiency.

The Importance of Biomarker Testing in mCRC

June 16th 2025

John L. Marshall, MD; Marwan G. Fakih, MD; Arvind N. Dasari, MD, MS; and Katrina S. Pedersen, MD, discuss how precision medicine has transformed metastatic colorectal cancer treatment through comprehensive molecular testing, targeted therapies like BRAF/EGFR inhibition and immunotherapy combinations for microsatellite instability-high tumors, and personalized approaches to treatment sequencing and dosing modifications that balance efficacy with quality of life considerations.

Dr Pederson on Novel Therapies for the Management of Targetable mCRC

May 13th 2024

Katrina S. Pedersen, MD, MS, discusses key updates in the therapeutic landscape for patients with molecularly targetable metastatic colorectal cancer.

Dr Pedersen on the Evolution of Immunotherapy in HCC

April 1st 2024

Katrina S. Pedersen, MD, MS, discusses the evolution of the role of immunotherapy in the treatment of patients with hepatocellular carcinoma.

Dr Pedersen on the Evolving Use of Cytoreductive Surgery for Peritoneal Carcinomatosis

March 13th 2024

Katrina S. Pedersen, MD, MS, discusses the evolving use of cytoreductive surgery for patients with peritoneal carcinomatosis.

Dr Pedersen on Updates in mCRC Management

March 1st 2024

Katrina S. Pedersen, MD, MS, discusses key updates and FDA approvals from 2023 in metastatic colorectal cancer.

x